27 August 2014 - 27 August 2014 - US digital diagnostic testing company Singulex Inc said Wednesday it would present 10 abstracts showing the value of its Single Molecule Counting  (SMC) tecnology in cardiovascular disease research at the European Society of Cardiology (ESC) Congress 2014, to be held in Barcelona, Spain on August 30-September 3.

The abstracts include the latest clinical and diagnostic data in cardiovascular disease and its comorbidities, generated by the precise quantification of biomarkers utilising SMC technology.

Four of these abstracts describe results from trials that used Singulex's highly-sensitive cardiac troponin I (cTnI) to examine the relationship between cTnI and heart failure, coronary heart disease and exercise-induced myocardial ischemia. Five others describe endothelin-1 (ET-1) and interleukin-6 (IL-6) biomarkers, and discoveries for their implications in heart disease and its comorbidities.

Furthermore, two abstracts cover research that investigated the relationship of glucagon like peptide-1 (GLP-1) to blood pressure and body fat mass in young, healthy adults. One abstract involves results of a trial that utilised a kidney injury molecule (KIM-1) assay to find if there is a correlation between KIM-1 and renal dysfunction in heart failure patients, since worsening kidney function is a comorbidity of heart failure.

A tenth abstract summarises data from a trial where the matrix metalloproteinase-9 (pMMP-9) assay was used to assess its ability to predict heart failure.

Findings for all of the afore-mentioned biomarkers were generated on Singulex's Erenna immunoassay system, available for research-use-only.

In addition, the company will present the first preview of its SMC-driven fully-automated in-vitro diagnostics system, Sgx Clarity System at the 2014 ESC Congress. The product is set to be introduced in the European Union (EU) in 2016.